Navigating first-line treatment decisions for EGFRM+ NSCLC: Extrapolating from Asian clinical trial experience (ID 1237)
Tackling Uncommon EGFR mutations: Efficacy of EGFR TKIs in NSCLC (ID 1238)
KRAS-mutant NSCLC treatment advances on the horizon (ID 1239)
